Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$1.96B |
$11.27
-0.13%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS (voclosporin) is an immunology/autoimmune therapy, aligning Aurinia's core business with immunology therapeutics.
|
$1.95B |
$14.86
-0.10%
|
|
IMNM
Immunome, Inc.
Primary modality across the pipeline is Antibody-Drug Conjugates (ADCs).
|
$1.95B |
$22.43
-1.86%
|
|
ATRC
AtriCure, Inc.
Pain-management devices (cryoSPHERE family, cryoXT) provide non-opioid analgesia, a key product category.
|
$1.94B |
$39.09
-5.72%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$1.89B |
$37.45
-2.90%
|
|
OLMA
Olema Pharmaceuticals, Inc.
Olema is a biotechnology company focused on oncology therapies, including palazestrant in ER+ breast cancer.
|
$1.86B |
$27.14
-7.04%
|
|
ANIP
ANI Pharmaceuticals, Inc.
ANI's Rare Disease/Brands expansion includes ophthalmic therapies ILUVIEN and YUTIQ acquired via Alimera, marking Ophthalmic Drugs as a direct product category.
|
$1.84B |
$84.85
-0.52%
|
|
AZTA
Azenta, Inc.
Genewiz genomic sequencing and broader SMS/Multiomics services align with Contract Research Organizations.
|
$1.83B |
$40.01
+0.25%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.83B |
$15.62
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$1.79B |
$40.85
+2.61%
|
|
HROW
Harrow Health, Inc.
Direct ophthalmic drug products (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) are core branded ophthalmic pharmaceuticals.
|
$1.77B |
$47.88
-1.26%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Company focuses on oncology therapeutics, including Revuforj and Niktimvo, placing Syndax in Biotech - Oncology.
|
$1.77B |
$20.50
-0.82%
|
|
ZYME
Zymeworks Inc.
Zymeworks develops oncology therapeutics, including zanidatamab and multiple ADC/MSAT platform programs.
|
$1.76B |
$23.48
-0.61%
|
|
SION
Sionna Therapeutics, Inc.
Lead candidates are oral small-molecule therapeutics (SION-719, SION-451) in clinical development.
|
$1.73B |
$39.12
+0.71%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.70B |
$25.66
-0.12%
|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$1.68B |
$33.29
+1.65%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$1.67B |
$31.00
+0.32%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$1.66B |
$40.99
+2.32%
|
|
NEO
NeoGenomics, Inc.
MRD-related diagnostics and companion diagnostics align with therapy selection and monitoring.
|
$1.65B |
$12.78
-0.43%
|
|
ARDX
Ardelyx, Inc.
Ardelyx's core offerings are oral, small-molecule therapeutics (IBSRELA and XPHOZAH) based on tenapanor.
|
$1.63B |
$6.75
-4.12%
|
|
ELVN
Enliven Therapeutics, Inc.
Directly develops oncology therapeutics (small-molecule kinase inhibitors) for cancer, including lead assets ELVN-001 (BCR-ABL) and ELVN-002 (HER2).
|
$1.58B |
$26.71
+6.14%
|
|
AGIO
Agios Pharmaceuticals, Inc.
Lead assets PYRUKYND (mitapivat) and tebapivat are oral small-molecule PK activators targeting red blood cell metabolism in rare hematologic diseases, representing Agios's core product strategy.
|
$1.58B |
$27.20
-2.18%
|
|
STOK
Stoke Therapeutics, Inc.
TANGO uses antisense oligonucleotides to upregulate the healthy gene copy, directly categorizing the company’s core assets as an oligonucleotide therapeutic.
|
$1.57B |
$28.70
-1.96%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA-300 is an oral FGFR3-selective small-molecule inhibitor; TYRA develops oral small-molecule therapeutics.
|
$1.53B |
$28.77
-0.86%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$1.49B |
$16.52
+3.48%
|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.47B |
$19.21
+1.88%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$1.46B |
$23.70
-1.58%
|
|
TNGX
Tango Therapeutics, Inc.
Directly develops oncology therapies (biotech) targeting genetically defined cancers, aligning with Biotech - Oncology.
|
$1.45B |
$13.00
+11.21%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.44B |
$45.56
-2.86%
|
|
KOD
Kodiak Sciences Inc.
Kodiak is developing ophthalmic drugs (intravitreal biologics) for retinal diseases, making Ophthalmic Drugs a core product category.
|
$1.43B |
$27.15
+1.69%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$1.42B |
$44.26
+0.58%
|
|
OCS
Oculis Holding AG
Direct ophthalmic drug products (OCS-01, OCS-02, OCS-05) are the core offerings: ophthalmic drugs.
|
$1.41B |
$25.23
+5.83%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
ORLADEYO is BioCryst's flagship oral small-molecule therapy for hereditary angioedema, a core product.
|
$1.40B |
$6.66
-7.18%
|
|
BHVN
Biohaven Ltd.
MoDE/TRAP degrader platforms and IgG/IgA-targeting efforts place Biohaven in Immunology Therapeutics.
|
$1.39B |
$13.13
+10.15%
|
Showing page 7 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
